Citadel Advisors’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-2,100
| Closed | -$204K | – | 10163 |
|
|
2019
Q3 | $204K | Sell |
2,100
-2,500
| -54% | -$250K | ﹤0.01% | 8131 |
|
|
2019
Q2 | $471K | Sell |
4,600
-1,900
| -29% | -$205K | ﹤0.01% | 6909 |
|
|
2019
Q1 | $740K | Sell |
6,500
-20,700
| -76% | -$1.52M | ﹤0.01% | 6120 |
|
|
2018
Q4 | $1.06M | Buy |
27,200
+18,100
| +199% | +$785K | ﹤0.01% | 5207 |
|
|
2018
Q3 | $496K | Sell |
9,100
-10,300
| -53% | -$704K | ﹤0.01% | 6713 |
|
|
2018
Q2 | $1.61M | Sell |
19,400
-8,100
| -29% | -$625K | ﹤0.01% | 4436 |
|
|
2018
Q1 | $1.83M | Buy |
27,500
+200
| +0.7% | +$11.5K | ﹤0.01% | 3873 |
|
|
2017
Q4 | $1.4M | Buy |
27,300
+18,100
| +197% | +$1.3M | ﹤0.01% | 4127 |
|
|
2017
Q3 | $820K | Buy |
9,200
+1,300
| +16% | +$98.7K | ﹤0.01% | 4594 |
|
|
2017
Q2 | $472K | Buy |
+7,900
| New | +$441K | ﹤0.01% | 5201 |
|
|
2016
Q4 | – | Sell |
-4,700
| Closed | -$282K | – | 8149 |
|
|
2016
Q3 | $282K | Sell |
4,700
-5,600
| -54% | -$323K | ﹤0.01% | 5771 |
|
|
2016
Q2 | $527K | Buy |
10,300
+3,500
| +51% | +$150K | ﹤0.01% | 4409 |
|
|
2016
Q1 | $201K | Buy |
6,800
+5,500
| +423% | +$173K | ﹤0.01% | 5639 |
|
|
2015
Q4 | $59K | Sell |
1,300
-21,200
| -94% | -$1.11M | ﹤0.01% | 7174 |
|
|
2015
Q3 | $939K | Buy |
22,500
+16,000
| +246% | +$835K | ﹤0.01% | 3899 |
|
|
2015
Q2 | $392K | Buy |
6,500
+4,500
| +225% | +$298K | ﹤0.01% | 5349 |
|
|
2015
Q1 | $155K | Buy |
+2,000
| New | +$115K | ﹤0.01% | 6446 |
|
Citadel Advisors's ONCE Position: Q4 2019 in Review
Citadel Advisors sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 654,852 shares — an estimated $63.5M sold.
Citadel Advisors first reported a position in ONCE in Q1 2015 and held it in 17 quarters. The position peaked at $69.4M in Q1 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Citadel Advisors reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Citadel Advisors sold 654,852 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $63.5M.
- Citadel Advisors first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 17 quarters.
- Citadel Advisors's Spark Therapeutics, Inc. Common Stock position peaked at $69.4M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.